Cancel anytime
LMF Acquisition Opportunities Inc (ICU)ICU
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: ICU (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: 18.06% | Upturn Advisory Performance 5 | Avg. Invested days: 29 |
Profits based on simulation | Stock Returns Performance 2 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: 18.06% | Avg. Invested days: 29 |
Upturn Star Rating | Stock Returns Performance 2 |
Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 5 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.25M USD |
Price to earnings Ratio - | 1Y Target Price 18 |
Dividends yield (FY) - | Basic EPS (TTM) -18.55 |
Volume (30-day avg) 83876 | Beta -1.1 |
52 Weeks Range 3.25 - 42.92 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 21.25M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Dividends yield (FY) - | Basic EPS (TTM) -18.55 | Volume (30-day avg) 83876 | Beta -1.1 |
52 Weeks Range 3.25 - 42.92 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -308.09% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 23213339 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.13 |
Shares Outstanding 4191780 | Shares Floating 4043861 |
Percent Insiders 8.7 | Percent Institutions 4.13 |
Trailing PE - | Forward PE - | Enterprise Value 23213339 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.13 | Shares Outstanding 4191780 | Shares Floating 4043861 |
Percent Insiders 8.7 | Percent Institutions 4.13 |
Analyst Ratings
Rating 4 | Target Price 1 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 1 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
LMF Acquisition Opportunities Inc. Comprehensive Overview
Company Profile
LMF Acquisition Opportunities Inc. (LMFAU) is a blank check company formed in 2022 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. LMF Acquisition is not currently generating any revenue or operations, thus, lacks much of the information presented in a normal company profile.
Top Products and Market Share
Not applicable due to the company being pre-revenue and pre-acquisition.
Total Addressable Market
LMF Acquisition's target market is the vast and diverse global mergers and acquisitions landscape. Determining the total addressable market is contingent on the specific target business(es) it chooses to pursue.
Financial Performance
No financial data is currently available to analyze as the company is pre-revenue and awaiting its first acquisition.
Dividends and Shareholder Returns
LMF Acquisition currently does not offer any dividends, as it is pre-revenue and hasn't yet completed an acquisition.
Growth Trajectory
Due to the pre-acquisition and pre-revenue stage, historical growth analysis or future projections are not applicable at this point.
Market Dynamics
LMF Acquisition operates in the highly competitive M&A environment, influenced by factors like economic conditions, target industry trends, access to capital, and regulatory issues. Its success will hinge on identifying an attractive target with strong growth potential and executing the business combination effectively.
Competitors
A comprehensive list of competitors is impossible as the company hasn't chosen an acquisition target yet. However, potential competitors include other blank-check companies seeking mergers or acquisitions in similar sectors.
Potential Challenges and Opportunities
Challenges faced by LMF Acquisition could include identifying an appropriate M&A target, effectively integrating the target business, competing with other acquirers, and navigating a potentially volatile M&A market. Opportunities lie in identifying high-potential target businesses with growth potential and securing advantageous acquisition terms.
Recent Acquisitions
Not applicable - No acquisitions have occurred to date.
AI-Based Fundamental Rating
An AI-based rating for LMF Acquisition is not possible at this time as the company lacks operational and financial data for analysis.
Sources and Disclaimers
- LMF Acquisition website: https://lmfacquisition.com/
Disclaimer:
This report provides an overview of LMF Acquisition Opportunities Inc. based on publicly available information. It should not be considered professional financial advice, and users should conduct their own research before making investment decisions. The information presented may contain errors or omissions, and accuracy is not guaranteed. Investment decisions should consider factors like individual risk tolerance and financial circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LMF Acquisition Opportunities Inc
Exchange | NASDAQ | Headquaters | Denver, CO, United States |
IPO Launch date | 2022-10-28 | CEO, President & Executive Director | Mr. Eric Schlorff |
Sector | Healthcare | Website | https://www.seastarmedical.com |
Industry | Biotechnology | Full time employees | 12 |
Headquaters | Denver, CO, United States | ||
CEO, President & Executive Director | Mr. Eric Schlorff | ||
Website | https://www.seastarmedical.com | ||
Website | https://www.seastarmedical.com | ||
Full time employees | 12 |
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.